Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment
Abdallah, N., Selim, N., Mahmoud, L., Abdelkreem, S., Ibrahim, A. (2022). Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment. EKB Journal Management System, 3(2), 97-109. doi: 10.21608/ejmr.2022.236208
Nilly Helmy Abdallah; Nourhan Mohamed Selim; Lamia Mohamed Mahmoud; Shaimaa Ali Abdelkreem; Ahmed Amin Ibrahim. "Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment". EKB Journal Management System, 3, 2, 2022, 97-109. doi: 10.21608/ejmr.2022.236208
Abdallah, N., Selim, N., Mahmoud, L., Abdelkreem, S., Ibrahim, A. (2022). 'Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment', EKB Journal Management System, 3(2), pp. 97-109. doi: 10.21608/ejmr.2022.236208
Abdallah, N., Selim, N., Mahmoud, L., Abdelkreem, S., Ibrahim, A. Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment. EKB Journal Management System, 2022; 3(2): 97-109. doi: 10.21608/ejmr.2022.236208

Study of Epidermal Growth Factor Gene Polymorphism in Hepatitis C Virus Induced Liver Cirrhosis with or without Treatment

Egyptian Journal of Medical Research
Article 6, Volume 3, Issue 2, April 2022, Page 97-109  XML PDF (334.48 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.236208
View on SCiNiTO View on SCiNiTO
Authors
Nilly Helmy Abdallah1; Nourhan Mohamed Selim1; Lamia Mohamed Mahmoud1; Shaimaa Ali Abdelkreem2; Ahmed Amin Ibrahim1
1Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
2Clinical Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
Abstract
Background: Epidermal growth factor (EGF) is a mitogen for hepatocytes, and plays a critical role in liver tissue regeneration. Many signaling pathways especially pathways that regulate the physiological processes such as tumor cells growth, differentiation, migration, apoptosis, and angiogenesis had been studied in the era of HCC development such as the EGF signal pathway.During the past few years, there have been enormous efforts to understand the structure and life cycle of hepatitis C virus (HCV) as well as to develop specific medications targeting different viral proteins such as NS3/4A protease, NS5B polymerase, and NS5A replication complex. The discovery of direct acting antiviral agents (DAAs) represented a revolution in the management of chronic hepatitis C virus infection Objectives: to investigate polymorphism of the gene encoding EGF in HCV-induced liver cirrhosis whether receiving antiviral treatment or not.Methods: Sixty Egyptian patients were enrolled in the study. Twenty patients pre-diagnosed as HCV-induced liver cirrhosis and received antiviral treatment in the form of Daklatasvir, Sofosbuvir and Ribavirin for 3 months and sustained virological response (SVR) was obtained, 20 patients diagnosed as HCV-induced liver cirrhosis and not receiving treatment yet, and 20 healthy person of matched age and sex as control group). Genotyping for EGF gene was performed by real time PCR.Results: With regards to polymorphism of EGF gene there are three genotypes; A/A, A/G and G/G that were detected in the three studied groups. The frequency of EGF gene polymorphism in HCV patients who received treatment was (AA 5%, AG 60%, GG 35%), while was (AA10%, AG 45%, GG 45%) in HCV patients who did not receive treatment. In control group, the frequency was (AA 65 %, AG 15%, GG 20%). Upon examining the allelic discrimination, A allele was present in 35% of HCV patient who received treatment versus 32.5% of HCV patient who did not receive treatment and 72.5% of control group. On the other hand, G allele was present in 65% of HCV patients who received treatment versus 67.5% of HCV patients who did not receive treatment and 17.5% of control group. Conclusion: No significant effect of antiviral treatment on EGF gene.
Keywords
HCV infection; Liver cirrhosis; Epidermal growth factor gene; Gene polymorphism; Egypt
References
  1. Younossi ZM, Stepanova M, Jacobson IM (2018): Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 47:259-267.
  2. Curry MP, O’Leary JG, Bzowej N (2015) : Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med.373:2618-2628.
  3. Zona L., Lupberger J., Sidahmed-Adrar N., Thumann C., Harris H.J., Barnes A., Florentin J., Tawar R.G., Xiao F., Turek M (2013) : HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor Complex. Cell Host Microbe.13:302–313.
  4. Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ (2015) : Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: A randomized trial. Ann Intern Med.163:809–817).
  5. Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S (2016) : Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol. 10:21–3).
  6. Tonjes RR, Lohler J, O’Sullivan JF, Kay GF, Schmidt GH, Dalemans W, Pavirani A, Paul D (1995) : Autocrine mitogen Ig EGF cooperates with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene. 10(4):765–768).
  7. Pavlov V1, Xiao Y, Gill R, Dishon A, Kotler M, Willner I. Amplified chemiluminescence surface detection of DNA and telomerase activity using catalytic nucleic acid labels. Anal Chem. (2004) Apr 1;76(7):2152-6).
  8. S. Abd-Elsalam, M. Sharaf-Eldin, S. Soliman, A. Elfert, R. Badawi, and Y. K. Ahmad (2017) : “Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice,” Archives of Virology, pp. 1–6.[10].
  9. Abdel-Razek,Waked (2015) :Optimal therapy in genotype 4 chronic hepatitis C: finally cured. Liver Int.;35 Suppl 1:27-34 ).
  10. G. Bertino, A. Ardiri, M. Proiti (2016): Chronic hepatitis C: this and the new era of treatment,” World Journal of Hepatology, vol. 8, no. 2, pp. 92–106.
  11. Carpenter, C.D.; Ingraham, H.A.; Cochet, C.; Walton, G.M.; Lazar, C.S.; Sowadski, J.M.; Rosenfeld, M.G.; Gill, G.N (1991) : Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J. Biol. Chem. 266, 575.5755).
  12. Xu W, Li Y, Wang X, Chen B, Liu S (2010) : Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. Med Oncol 27: 1389–1397.
  13. Fondon JW III, Hammock EA, Hannan AJ, King DG (2008) : Simple sequence repeats: genetic modulators of brain function and behavior. Trends Neurosci. 31:328–334.
  14. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K (2005) : Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene.24(11):1809–1819.
  15. Abbas E, Shaker O, Abd El Aziz G, Ramadan H, Esmat G (2012) : Epidermal growth factor gene polymorphism 61 A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma: a pilot study. Eur J Gastroenterol Hepatol; 24 (458-463).
  16. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC (2008) : Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299 (1): 53-60. 
  17. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O’Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group (2011) : A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology; 141 (1): 141-149. 
  18. Yuan JM, Fan Y, Ognjanovic S, Wang R, Berg DVD, Govindarajan S, Yu MC (2013) : Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC Gastroenterology 13: 32.
  19. Qi P, Wang H, Chen YM, Sun XJ, Liu Y, Gao CF (2009) : No association of EGF 5’UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology 41 (6): 555-560.
Statistics
Article View: 266
PDF Download: 113